Personal information
Biography
Currently, Dr. Ain is working as a postdoctoral scholar at the Department of Pathology, University of California, San Francisco, USA. Where she is spatially characterizing the tumor microenvironment using NanoString's GeoMax Digital Spatial Profiling (DSP) Technology. In addition, she developed a human esophageal organoid model and optimized an organotypic air-liquid interface (ALI) model system and genetically modifying them through CRISPR-CAS technology.
As a part of CRUK-GC-Stroming Cancer Team at the University of California, San Francisco, she utilized single-cell RNA sequencing (scRNA-seq) and gene expression analysis to determine the effects of chronic and acute bile acid (BA) exposure on the transcriptional reprogramming of fibroblasts, leading to the production of pro-inflammatory cytokines.
Dr. Ain has been served as an Assistant Professor of Biochemistry/Pharmaceutical Chemistry at the Department of Pharmaceutical Chemistry, Faculty of Pharmacy Hamdard University, Karachi, Pakistan and as a Visiting Assistant Professor of Molecular Biology/Genetics at the Department of Physical Therapy, Faculty of Health & Medicine, Hamdard University, Karachi, Pakistan.
Dr. Ain received a Ph. D. in Molecular Medicine from Dr. Panjwni Center for Molecular Medicine & Drug Research, International Center for Chemical & Biological Sciences, University of Karachi, Pakistan in Collaboration with Department of Dermatology & Allergic Disease University of Ulm Germany.
Dr. Ain Ph.D. research was focus on the investigation of the role of deregulated oxidative stress and kinase dependent signal transduction pathways and their related genes involved in the multiple types of cancers initiation and progression with the goal of discovery and development of new anticancer therapeutics.
She also has a background in neurological, metabolic and cardiovascular diseases, most particularly understanding the molecular pathways of Parkinson’s, Type-II diabetes and cardiovascular diseases, she worked for the identification of new therapeutic targets, biomarkers, and development of relative therapeutics.